Clinical Trials Logo

Panuveitis clinical trials

View clinical trials related to Panuveitis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06085079 Recruiting - Uveitis, Posterior Clinical Trials

Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study

Start date: June 1, 2022
Phase: Phase 4
Study type: Interventional

The objective of this study is to explore the efficacy of ixekizumab in treating patients with a diagnosis of non-infectious intermediate, posterior, panuveitis, or chronic steroid-dependent anterior uveitis who had failed treatment with a classic synthetic DMARD including methotrexate, mycophenolate, cyclosporin, azathioprine, cyclophosphamide and/or at least one anti-TNF agent including adalimumab, infliximab, etanercept, golimumab or certolizumab.

NCT ID: NCT05101928 Recruiting - Uveitis, Posterior Clinical Trials

Ozurdex Monotherapy Trial

OM
Start date: November 30, 2021
Phase: Phase 4
Study type: Interventional

This study will investigate the efficacy and safety of OZURDEX® (dexamethasone intravitreal implants; DEX, Allergan, Inc. Irvine, CA) as monotherapy for the treatment of non-infectious intermediate-, posterior- or panuveitis. This is a prospective randomized controlled clinical trial taking place at the University of Ottawa Eye Institute, Ottawa, Ontario, Canada, and other possible centers in Canada. Consecutive consenting subjects who meet inclusion/exclusion criteria will be selected to participate in this study. The subjects must have either non-infectious intermediate, posterior, or panuveitis. The subjects will be randomly chosen to be part of one of two groups; one group will receive DEX as monotherapy and the other group will receive oral prednisone. Approximately 84 eyes (42 per arm) will take part in study. The primary outcome will measure the proportion of eyes with a vitreous haze score of 0 six months post initial treatment. Secondary measures will include best corrected visual acuity (BCVA), central retinal thickness (CRT) measured by spectral-domain optical coherence tomography (SD-OCT), time to vitreous haze resolution and time to failure defined at number of months with DEX implant until an adjunct therapy is indicated. Baseline measurements will be recorded within 1 month prior to treatment in both groups, with follow up measurements collected at 0, 1, 2, 4, 6 and 12 months post-operatively.

NCT ID: NCT04521673 Recruiting - Clinical trials for Infectious Panuveitis

Pathogen Detection in Infectious Uveitis

Start date: October 1, 2020
Phase:
Study type: Observational

Infectious uveitis is a very important blinding disease. Some people who have been diagnosed with idiopathic uveitis may also have the activity of pathogens in the eye. However, due to the limitation of the amount of ocular samples, it is difficult to make a rapid and effective diagnosis of infection.Current study is to explore the infective cause of uveitis in China by using a broad diagnostic approach of detection.

NCT ID: NCT00407316 Recruiting - Uveitis Clinical Trials

Quality of Life and Visual Function in Uveitis Patients

Start date: June 2006
Phase: Phase 0
Study type: Observational

The purpose of this study was to measure the quality of visual function and quality of daily living in patients with anterior, posterior, and panuveitis.